Sun Pharma Considers Expanding Its Manufacturing Footprint in the US Amid Tariff Challenges

Sun Pharma is considering expanding its manufacturing presence in the United States. This comes as the Trump administration has imposed a 100 per cent tariff on branded and patented medicines. Richard Ascroft, CEO for Sun Pharma's North America business, mentioned in an analyst call that the company already has a manufacturing base in the US.

Representative image

Ascroft explained that the company is continuously evaluating its manufacturing operations. He stated, "We are kind of constantly assessing that manufacturing footprint, and we are open to considering this in the US in due time." However, he did not provide specific details about potential expansions.

Impact of Tariffs on Sun Pharma's Strategy

The current tariff situation is described as fluid and uncertain by Ascroft. This makes it challenging for Sun Pharma to predict how these tariffs might affect their generics or innovative medicines portfolio. The company is keeping all options open as they navigate these changes.

Sun Pharma's Executive Chairman, Dilip Shanghvi, highlighted ongoing efforts to introduce new treatments. The company plans to launch UNLOXCYT, an FDA-approved treatment for advanced skin cancer, in the US during the second half of FY26. Additionally, they aim to file ILUMYA psoriatic arthritis SPLA in the same timeframe.

Research and Development Investments

Shanghvi also emphasised Sun Pharma's commitment to investing in research and development. The company is focused on building a robust pipeline for its innovative medicines business. This investment aims to support future growth and ensure a steady flow of new products.

The company's strategy reflects its adaptability in response to changing market conditions. By exploring local manufacturing options and investing in R&D, Sun Pharma aims to strengthen its position in the US market despite tariff challenges.

Sun Pharma's approach demonstrates a proactive stance towards maintaining competitiveness. The focus on launching new treatments and expanding manufacturing capabilities highlights their commitment to growth and innovation.

With inputs from PTI